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 PD is a major neurodegenerative disease of the elderly 
 PD is accompanied by the accumulation of intracellular lesions in the 
brain 
 These lesions, named Lewy Bodies, contain α-synuclein in an 
aggregated form (Fig. 1). 
 As PD progresses, aggregate density increases and spreads in a 
stereotypical fashion (Fig. 2) 
 A third of cases go on to develop Lewy body dementia (LBD), 
characterized by cortical deposition of α-synuclein aggregates 
 PROBLEM: Currently no pre-mortem biomarker for Lewy bodies exists. 
 Biomarkers are needed for early detection, staging, and 
differential diagnosis of PD and especially LBD 
Figure 1: α-synuclein  aggregation in neurons (R&D Systems, 2014).  
ABSTRACT 
Synucleinopathies are neurodegenerative diseases characterized by 
the abnormal accumulation of α-synuclein protein aggregates in the 
brain. Parkinson’s Disease, the leading movement disorder and 
synucleinopathy, encompasses roughly 9 million people worldwide 
and costs in the United States alone total $25 billion yearly. However, 
there are no standard diagnostic tests for a biological marker of 
Parkinson’s, such as a blood test or imaging scan. Difficulty in 
designing an imaging agent stems from the challenges of crossing the 
blood brain barrier, binding selectively to authentic lesions, and 
remaining low risk for human patients. This study aims to create an 
imaging agent that can detect and stage α-synuclein distribution in 
vivo (live in the patient) via positron emission tomography. Using 
immunohistochemical methods, human tissue was stained using a 
commercially available polyclonal anti-α-synuclein antibody and 
imaged using a con-focal microscope. Tissue stained with our small 
molecules tagged with a fluorescent ligand recapitulated the images of 
the positive control, validating that our molecule bound to the target. 
Preliminary data have provided promising results of the development 
of an imaging agent that binds authentically to α-synuclein and has 
the characteristics necessary to pass the blood brain barrier while 
remaining safe for human consumption. To continue verification, 
further testing will be done against Tau and β-amyloid protein to 
ensure the molecule’s selectivity for α-synuclein. Successful 
completion of this project will provide an objective diagnostic tool for 
physicians and patients. This tool will be critical in earlier diagnosis 
and staging of disease, aiding patients and healthcare providers 
towards better medical treatment and disease outcome. 
APPROACH 
Hypothesis: radio-labeled small-molecule probes capable of 
selectively binding α-synuclein aggregates could provide premortem 
assessment of synucleinopathies through whole brain imaging 
 
 
 
Figure 3: Positron emission  
tomography (PET). This whole-brain 
imaging technique can capture spatial 
distribution of diverse biomarkers. 
 
 
  Barriers to progress 
Probes must be α-synuclein selective  
Confounding binding sites are present in Ab and Tau 
aggregates 
Probes must pass the blood brain barrier 
 clogP (hydrophobicity): 2-4 
 Topological polar surface area (tPSA): <70 Å2 
Probes must have appropriate pharmacokinetics (PK) 
Rapid uptake and wash out 
 
 This project seeks to identify compounds that meet these 
requirements. 
 Identify candidate imaging agents 
 Histochemically stain human brain tissue  
 A commercially available antibody was used to stain PD tissue 
for comparison use with candidate molecules 
 PD tissue as positive control 
 AD tissue as negative control 
 
4. A fluorescent candidate small-molecule did not stain tau  lesions (Fig. 6D) 
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 α-synuclein aggregates are a tractable target for small-molecule 
radiotracer development 
 Binds recombinant α-synuclein selectively over tau and Aβ 
 Binds authentic Lewy bodies in PD tissue 
 Appropriate clogP, tPSA, and PK values suggest the scaffold class 
may have utility in vivo 
 FUTURE STUDIES 
 Structure activity relationship analysis to identify lead molecule 
  Preparation of radiolabeled compounds for advanced preclinical 
investigation 
 Direct binding experiments 
 Distribution, metabolism, and pharmacokinetics 
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Figure 4: Polar plot (signal), where the spokes correspond to displacement AC50 in units of 
nM. As one moves from center to outer rings, affinity drops.  Note that AC50 is not 𝐾𝑖.  Divide 
numbers by ~2 for 𝐾𝑖. Compounds 1-9 synthesized, tested, and results ordered with respect to 
α-synuclein (SNCA) displacement activity (blue).  Aβ (green) is present at high concentrations in 
brain and obscures imaging of Tau and SNCA. Figure 2:  Progression of PD (Braak, 2002) 
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Figure 6: Candidate molecule does not stain AD brain lesions 
 AD hippocampus examined by confocal fluorescence 
microscopy. A, autofluorescence; B, ThS stain.  Both panels A 
and B were captured at λex = 445, λem = 480/40. C, 
autofluorescence (same section as panel A, but captured at 
different wavelengths); D, ligand stain (100 μM).  Both panels C 
and D were captured at λex = 515, λem = 550/49.  ThS, but not 
ligand, stains neurofibrillary pathology. 
Figure 5: Candidate molecule stains PD brain lesions 
Parkinson’s disease substantia nigra examined by confocal fluorescence 
microscopy.  A, autofluorescence; B, 0.5 μg/ml commercially available sheep 
polyclonal antibody ab6162/Texas red-anti-sheep secondary antibody; C, ligand 
stain (100 μM).  Panels A and C were captured at λex = 515, λem = 550/49.  Panel B 
was captured at λex = 561, λex = 625/90.  Both antibody and ligand stain Lewy 
bodies in substantia nigra. 
Candidate molecules stains PD brain lesions 
DISCUSSION 
Figure 7: Preliminary PK data, rapid uptake/washout 
clogP = 3.63 
tPSA = 57.9 
clogP = 2.89 
tPSA = 70.8 
1. Candidate small molecules express appropriate binding specificity, 
hydrophobicity and tPSA  (Fig. 4) 
RESULTS (continued) RESULTS (continued) 
5. Preliminary data shows appropriate pharmacokinetics for 
rapid uptake and wash out (Fig. 7) 
2. Tissue sections prepared from the substantia nigra region of authentic 
PD brain demonstrate Lewy bodies.(Fig. 5AB)  
3. A fluorescent candidate small-molecule successfully stained Lewy 
bodies (Fig. 5C) 
 
